Sanofi has reported full-year 2025 revenue of EUR 43.6 billion (approximately USD 50.8 billion), representing 9.9% growth at constant exchange rates. The company's immunology franchise, led by the blockbuster drug Dupixent (dupilumab), was the primary growth driver, with the therapy's sales increasing 25.2% to EUR 15.714 billion (USD 18.29 billion). Other notable performers included the haemophilia treatment Altuviiio (efanesoctocog alfa), which saw 77.6% growth, and the Pompe disease therapy Nexviazyme (avalglucosidase alfa). Revenue in the US market grew strongly by 16.3%, while the Chinese market reported a stable 2.0% increase.

During 2025, Sanofi successfully launched three new products: Qfitlia (fitusiran) for haemophilia, Wayrilz (rilzabrutinib) for immune thrombocytopenia, and the Nuvaxovid COVID-19 vaccine. The company's pipeline also advanced, with positive Phase III results for the OX40L inhibitor amlitelimab in atopic dermatitis, and the initiation of four Phase III trials for the TL1A inhibitor duvakitug in inflammatory bowel disease. Following the divestiture of its consumer healthcare unit Opella, which generated EUR 10.4 billion, Sanofi plans to reinvest in R&D and M&A, forecasting high single-digit sales growth for 2026.

According to PharmCube's NextBiopharm® database, Sanofi has nine therapies under review that could hit the market soon. Click here to request a free trial for NextBiopharm®.